Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Nichi-Iko to Acquire Teva Takeda’s Generic Business
July 30, 2020
- Healios Starts Enrolling COVID-19 Patients in ARDS Cell Therapy Program
July 30, 2020
- Life Science Institute’s Muse Cell Therapy Effective in Epidermolysis Bullosa
July 30, 2020
- Otsuka Files Japan NDA for Preventive Treatment of Migraines
July 30, 2020
- Generic APIs at Crossroads - 1: Sawai Quality Chief Says Current Biz Structure Hampers Manufacturing Repatriation
July 29, 2020
- Santen Bags Rights to Osmotica’s Droopy Eyelid Drug
July 29, 2020
- Eisai, DeNA Launch Smartphone App for Dementia Prevention
July 29, 2020
- Ibrance Now Available in Tablet Forms: Pfizer Japan
July 29, 2020
- Pfizer Japan Has Different Interpretation on Lyrica Patent Ruling
July 29, 2020
- Novartis Links Up with Ehime Pref., Ehime Univ. to Fuel Cardiovascular Disease Prevention
July 29, 2020
- Chugai’s Half-Year Earnings Surge on Actemra/Hemlibra Exports
July 28, 2020
- EU Panel Gives Thumbs-Up to Avastin Biosimilar
July 28, 2020
- Daiichi Sankyo, AstraZeneca to Collaborate for Another ADC
July 28, 2020
- Lyrica Expected to Face Generic Onslaught by Year’s End as Patent Ruled Invalid
July 28, 2020
- EU Panel Backs Kyowa Kirin’s Crysvita for Adult XLH
July 28, 2020
- StemRIM Bags 1.7 Billion Yen from Shionogi for Expanded Deal on Regeneration-Inducing Medicine
July 28, 2020
- Chugai, Biofourmis to Develop Digital Solution to Objectively Assess Endometriosis Pain
July 27, 2020
- Astellas Earns NIH Grant for Potential Opioid Use Disorder Med
July 27, 2020
- Dosing of Low-Dose COVID-19 Vaccine Completed: AnGes PI/II Study
July 27, 2020
- Daiichi Sankyo Inks ADC Pact with Gustave Roussy
July 27, 2020
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…